No Data
Express News | Summary of shareholdings reductions by listed companies on November 26.
GenScript Biotech Corporation (301509.SZ): Qilu Investment, Blue Zone Fund, and Qingsong Investment plan to collectively reduce their shareholding by no more than 9%.
On November 26th, Gelonhui reported that Jinkai Life Science (301509.SZ) announced its plan to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading. Blue Zone Fund also plans to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading. Qingsong Investment also plans to reduce its shares by no more than 3,612,000 shares (3% of the total share capital) through block trading and bulk trading.
Express News | Jinkai Life Science: Shareholders plan to collectively reduce their shareholding by no more than 9% of the company's shares.
Jinkai Shengke: Report for the third quarter of 2024
Genecast Biotechnology (301509.SZ): The company's products do not involve starch or other fillers and excipients.
Golden Triumph October 23rd | Jin Kaiseng Science (301509.SZ) stated on the investor interaction platform that the company provides small molecule CDMO services, and the company's products do not involve starch and other fillers and excipients.
Jinkai Life Sciences (301509.SZ): focusing on developing European and Asia-Pacific customer base.
Geelong September 11th | Jinkai Life Sciences (301509.SZ) stated at the investor relations event that the company has been actively adjusting and has taken various key measures, including: 1. Strengthening the BD team, fully leveraging the international BD team and customer cni resource index advantages, focusing on developing customers in Europe and Asia-Pacific countries, actively expanding business incrementally on the basis of striving for existing customer project orders; 2. Fully leveraging the strategic support role of the USA GMP production base and R&D center, while hedging risks, quickly achieving performance contribution from the base and introducing more projects; 3. Fully leveraging the pharmaceutical CDMO field.
No Data
No Data